Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 645-652

  Beall, Howard D ^a   Liu, Yafei ^b,c   Siegel, David ^a   Bolton, Emiko M ^a   Gibson, Neil W ^b,d   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c STANFORD UNIVERSITY   (United States)

^d PFIZER INC   (United States)

Author keywords

bioreductive activation; cytotoxicity; DNA strand breaks; DT diaphorase; genotoxicity; streptonigrin

Indexed keywords

DEFEROXAMINE; DICOUMAROL; DIVALENT CATION; HYDROXYL RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN;

ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG METABOLISM; ENZYME ACTIVITY; GENOTOXICITY; HUMAN; HUMAN CELL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REDUCTION;

EID: 0029969531     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)00223-5     Document Type: Article

References (41)

1. Rao KV and Cullen WP, Streptonigrin, an antitumor substance. In: Antibiotics Annual 1959-1960 (Eds. Welch H and Marti-Ibanez F), pp. 950-953. Medical Encyclopedia, Inc., New York, 1960.
2. Oleson JJ, Calderella LA, Mjos KJ, Reich AR, Thie RS and Toplin I. The effects of streptonigrin on experimental tumors. Antibiot Chemother 11: 158-164, 1961.
3. Teller MN, Wagshul SF and Woolley GW, Transplantable human tumors in experimental chemotherapy: Effects of Streptonigrin on HS#1 and HEp#3 in the rat. Antibiot Chemother 11: 165-173, 1961.
4. Reilly HC and Sigiura K, An antitumor spectrum of streptonigrin. Antibiot Chemother 11: 174-177, 1961.
5. Hackethal CA, Golbey RB, Tan CTC, Karnofsky DA and Burchenal JH, Clinical observations on the effects of streptonigrin in patients with neoplastic disease. Antibiot Chemother 11: 178-183, 1961.
6. Humphrey EW and Blank N, Clinical experience with streptonigrin. Cancer Chemother Rep 12: 99-103, 1961.
7. Rivers SL, Whittington RM and Medrek TJ, Treatment of malignant lymphomas with methyl ester of streptonigrin (NSC 45384). Cancer 19: 1377-1385, 1966.
8. Kaung DT, Whittington RM, Spencer HH and Patno ME, Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of chronic lymphocytic leukemia. Cancer 23: 597-600, 1969.
9. Kaung DT, Whittington RM, Spencer H and Patno ME, Comparison of chlorambucil and streptonigrin (NSC-45383) in the treatment of malignant lymphomas. Cancer 23: 1280-1283, 1969.
10. Banzet P, Jacquillat C, Civatte J, Puissant A, Maral J, Chastang C, Israel L, Belaich S, Jourdain J-C, Weil M and Auclerc G, Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 41: 1240-1248, 1978.
11. Forcier RJ, McIntyre OR, Nissen NI, Pajak TF, Glidewell O and Holland JF, Combination chemotherapy of non-Hodgkin lymphoma. Med Pediatr Oncol 4: 351-362, 1978.
12. Hadju J and Armstrong EC, Interaction of metal ions with streptonigrin. 1. Formation of copper(II) and zinc(II) complexes of the antitumor antibiotic. J Am Chem Soc 103: 232-234, 1981.
13. Sugiura Y, Kuwahar J and Suzuki T, DNA interaction and nucleotide sequence cleavage of copper-streptonigrin. Biochim Biophys Acta 782: 254-261, 1984.
14. White JR, Streptonigrin-transition metal complexes: Binding to DNA and biological activity. Biochem Biophys Res Commun 77: 387-391, 1977.
15. Sinha BK, Irreversible binding of reductively activated streptonigrin to nucleic acids in the presence of metals. Chem Biol Interact 36: 179-188, 1981.
16. Cone R, Hasan SK, Lown JW and Morgan AR. The mechanism of the degradation of DNA by streptonigrin. Can J Biochem 54: 219-223, 1976.
17. Mizuno NS, Effects of streptonigrin on nucleic acid metabolism of tissue culture cells. Biochem Biophys Acta 108: 394-403, 1965.
18. Cohen MM, Shaw MW and Craig AP, The effects of streptonigrin on cultured human leukocytes. Proc Nad Acad Sci USA 50: 16-24, 1963.
19. Yamashita Y, Kawada S-Z, Fujii N and Nakano H, Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 50: 5841-5844, 1990.
20. Lown JW, Sim S-K and Chen H-H, Hydroxyl radical production by free and DNA-bound aminoquinone antibiotics and its role in DNA degradation. Electron spin resonance detection of hydroxyl radicals by spin trapping. Can J Biochem 56: 1042-1047, 1978.
21. Bachur NR, Gordon SL, Gee MV and Kon H, NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 76: 954-957, 1979.
22. Ernster L, DT-diaphorase. Methods Enzymol 10: 309-317, 1967.
23. Thor H, Smith MT, Hartzell P, Bellomo G, Jewell SA and Orrenius S, The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells. J Biol Chem 257: 12419-12425, 1982.
24. Lind C, Hochstein P and Ernster L, DT-Diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation. Arch Biochem Biophys 216: 178-185, 1982.
25. Siegel D, Gibson NW, Preusch PC and Ross D, Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483-7489, 1990.
26. Siegel D, Gibson NW, Preusch PC and Ross D, Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7293-7300, 1990.
27. Lee C-S, Hartley JA, Berardini MD, Butler J, Siegel D, Ross D and Gibson NW, Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 31: 3019-3025, 1992.
28. Walton MI, Bibby MC, Double JA, Plumb JA and Workman P, DT-diaphorase activity correlates with sensitivity to the indoloquinone E09 in mouse and human colon carcinomas. Eur J Cancer 28A: 1597-1600, 1992.
29. Knox RJ, Boland MP, Friedlos F, Coles B, Southan C and Roberts JJ, The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmocol 37: 4671-4677, 1988.
30. Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW and Ross D, Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54: 3196-3201, 1994.
31. Beall HD, Murphy AM, Siegel D, Hargreaves RHJ, Butler J and Ross D, NAD(P)H:quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 48: 499-504, 1995.
32. Schlager JJ and Powis G, Cytosolic NAD(P)H:quinone acceptor oxidoreductase in human normal and tumor tissue. Effects of cigarette smoking and alcohol. Int J Cancer 45: 403-409, 1990.
33. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD Jr and Ross D, Elevated DT-diaphorase activity and messenger RNA content in human non-small lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52: 4752-4757, 1992.
34. 1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmocol 42: 1021-1027, 1991.
35. Workman P, Walton MI, Bailey SM and Suggett NR, Enzyme-directed bioreductive drug development: Molecular features which favour activation of quinone bioreductives by DT-diaphorase. Br J Cancer 64 (Suppl 15): 4, 1991.
36. Berger MS, Talcott RE, Rosenblum ML, Silva M, Ali-Osman F and Smith MT, The use of quinones in brain tumor chemotherapy. Preliminary results from preclinical investigations. J Toxicol Environ Health 16: 713-719, 1985.
37. Kohn KW, Ewig RAG, Erickson LC and Zwelling LA, Measurement of strand breaks and cross-links by alkaline elution. In: DNA Repair : A Laboratory Manual of Research Procedures (Eds. Friedberg EC and Hanowalt PC), pp. 379-401. Marcel Dekker, New York, 1981.
38. Vermillion VL and Coon MJ, Purified liver microsomal NADPH-cytochrome P450 reductase. J Biol Chem 253: 2694-2704, 1978.
39. Stirpe F and Della Corte E, The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). J Biol Chem 244: 3855-3863, 1969.
40. Paull K, Camalier R, Fitzsimmons SA, Lewis AD, Workman P and Grever M, Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel. Proc Am Assoc Cancer Res 35: 369, 1994.
41. Traver RD, Horikoshi T, Danenberg KD, Stadibauer THW, Danenberg PV, Ross D and Gibson NW, NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52: 797-802, 1992.